KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Operating Expenses (2016 - 2026)

Fulgent Genetics' Operating Expenses history spans 12 years, with the latest figure at $56.1 million for Q1 2026.

  • On a quarterly basis, Operating Expenses rose 16.56% to $56.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $229.9 million, a 24.04% increase, with the full-year FY2025 number at $222.0 million, up 22.55% from a year prior.
  • Operating Expenses hit $56.1 million in Q1 2026 for Fulgent Genetics, down from $68.8 million in the prior quarter.
  • Over the last five years, Operating Expenses for FLGT hit a ceiling of $176.4 million in Q4 2023 and a floor of $39.6 million in Q3 2023.
  • Historically, Operating Expenses has averaged $55.7 million across 5 years, with a median of $48.0 million in 2024.
  • Biggest five-year swings in Operating Expenses: skyrocketed 255.98% in 2023 and later crashed 72.79% in 2024.
  • Tracing FLGT's Operating Expenses over 5 years: stood at $49.5 million in 2022, then skyrocketed by 255.98% to $176.4 million in 2023, then plummeted by 72.79% to $48.0 million in 2024, then soared by 43.42% to $68.8 million in 2025, then decreased by 18.47% to $56.1 million in 2026.
  • Business Quant data shows Operating Expenses for FLGT at $56.1 million in Q1 2026, $68.8 million in Q4 2025, and $50.9 million in Q3 2025.